Journal
Blood Advances
Publication Date
5-12-2026
Volume
10
Issue
9
First Page
3011
Last Page
3019
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2025017914
Rights and Permissions
Lewis KL, Assouline SE, Baker R, Bartlett NL, El-Sharkawi D, Giri P, Ku M, Matasar M, Schuster S, Radford J, Wei MC, Yin S, Kwan A, To I, Raghavan V, Budde LE, Cheah CY. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation. Blood Adv. 2026 May 12;10(9):3011-3019. doi: 10.1182/bloodadvances.2025017914. © 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Lewis, Katharine L; Bartlett, Nancy L; and et al., "Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation." Blood Advances. 10, 9. 3011 - 3019. (2026).
https://digitalcommons.wustl.edu/oa_4/7317
Additional Links
Supplemental material is available for this article at publisher site.
